Difference between revisions of "Part:BBa K4165156"
| Line 9: | Line 9: | ||
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively). | The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively). | ||
| − | |||
| − | |||
| − | |||
===Dry Lab=== | ===Dry Lab=== | ||
| Line 33: | Line 30: | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | ||
</html> | </html> | ||
| + | |||
| + | <!-- --> | ||
| + | <span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span> | ||
| + | <partinfo>BBa_K4165156 SequenceAndFeatures</partinfo> | ||
| + | |||
Revision as of 13:54, 6 October 2022
MM2 Peptide
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively).
Dry Lab
Modeling
MM2 is modeled by AlphaFold2, ITASSER and TrRosetta, best model obtained from TrRosetta.
Figure 1.: Predicted 3D structure of Synthetic peptide MM2.
Table 1: Quality assessment parameters of MM2 model.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).